Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods.

Tytuł:
Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods.
Autorzy:
Shams R; Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .; Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .
Saberi S; Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; HPGC Research Group, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Zali M; Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sadeghi A; Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ghafouri-Fard S; Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Aghdaei HA; Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .
Źródło:
Scientific reports [Sci Rep] 2020 May 05; Vol. 10 (1), pp. 7559. Date of Electronic Publication: 2020 May 05.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Gene Expression Regulation, Neoplastic*
Oligonucleotide Array Sequence Analysis*
Computational Biology/*methods
MicroRNAs/*metabolism
Pancreatic Neoplasms/*diagnosis
Area Under Curve ; Biomarkers/metabolism ; Case-Control Studies ; Cluster Analysis ; Gene Expression Profiling ; Humans ; Multivariate Analysis ; Protein Interaction Mapping ; Reproducibility of Results ; Sensitivity and Specificity
References:
Br J Cancer. 2013 Feb 19;108(3):644-52. (PMID: 23361059)
Int J Cancer. 2017 Jul 15;141(2):231-241. (PMID: 28240774)
Am J Cancer Res. 2015 Feb 15;5(3):1180-9. (PMID: 26045996)
Expert Rev Proteomics. 2009 Dec;6(6):675-89. (PMID: 19929612)
Int J Cancer. 2009 Dec 1;125(11):2520-7. (PMID: 19637314)
Int J Oncol. 2016 Apr;48(4):1688-700. (PMID: 26892887)
N Engl J Med. 2004 Mar 18;350(12):1200-10. (PMID: 15028824)
Sci Rep. 2019 Jun 4;9(1):8265. (PMID: 31164669)
Science. 2008 Sep 26;321(5897):1801-6. (PMID: 18772397)
Bioinformatics. 2011 Feb 1;27(3):431-2. (PMID: 21149340)
J Clin Oncol. 2009 Dec 1;27(34):5848-56. (PMID: 19884536)
Lancet. 2016 Jul 2;388(10039):73-85. (PMID: 26830752)
World J Gastrointest Oncol. 2014 Jan 15;6(1):22-33. (PMID: 24578785)
Oncotarget. 2015 Jul 10;6(19):17391-403. (PMID: 26041879)
Sci Rep. 2017 Jun 23;7(1):4150. (PMID: 28646161)
Pancreas. 2013 Oct;42(7):1107-13. (PMID: 24048453)
Pancreas. 2009 Jul;38(5):e137-50. (PMID: 19550273)
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. (PMID: 28874546)
Int J Cancer. 2011 Mar 1;128(5):1057-68. (PMID: 20473933)
PLoS One. 2012;7(3):e33663. (PMID: 22479426)
Clin Transl Oncol. 2014 Apr;16(4):374-9. (PMID: 23881463)
Cancer Res. 2009 Feb 15;69(4):1536-44. (PMID: 19208833)
Int J Clin Exp Med. 2014 Dec 15;7(12):5226-34. (PMID: 25664025)
J Cancer Res Clin Oncol. 2017 Jan;143(1):83-93. (PMID: 27631726)
BMC Med Res Methodol. 2002;2:4. (PMID: 11914137)
Oncol Lett. 2017 Jul;14(1):111-118. (PMID: 28693142)
PeerJ. 2018 Mar 26;6:e4551. (PMID: 29607263)
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. (PMID: 23193258)
Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6062-6069. (PMID: 31364107)
Dig Dis Sci. 2017 Jul;62(7):1827-1839. (PMID: 28528374)
Lung Cancer. 2016 Jan;91:15-22. (PMID: 26711929)
Oncotarget. 2017 Aug 18;8(44):77028-77040. (PMID: 29100367)
Int J Cancer. 2012 Aug 1;131(3):683-91. (PMID: 21913185)
Clin Cancer Res. 2017 May 15;23(10):2391-2399. (PMID: 28143873)
J Gastrointest Cancer. 2015 Sep;46(3):201-11. (PMID: 25972062)
Cell Mol Biol (Noisy-le-grand). 2017 Oct 31;63(10):99-105. (PMID: 29096749)
Cancer Epidemiol. 2016 Dec;45:98-107. (PMID: 27780077)
BMC Cancer. 2017 Jan 7;17(1):33. (PMID: 28061765)
PLoS One. 2015 Feb 23;10(2):e0118220. (PMID: 25706130)
Gut. 2013 Mar;62(3):339-47. (PMID: 23135763)
PLoS One. 2018 Dec 27;13(12):e0209750. (PMID: 30589909)
Nucleic Acids Res. 2018 Jan 4;46(D1):D360-D370. (PMID: 29194489)
BMC Cancer. 2016 May 16;16:315. (PMID: 27184257)
Eur Urol. 2015 Jan;67(1):33-41. (PMID: 25129854)
BMC Genomics. 2016 Oct 17;17(Suppl 9):751. (PMID: 27766962)
Gynecol Oncol. 2012 Mar;124(3):589-97. (PMID: 22115851)
Cancer Prev Res (Phila). 2015 Feb;8(2):165-73. (PMID: 25538087)
N Engl J Med. 2010 Apr 29;362(17):1605-17. (PMID: 20427809)
BMC Bioinformatics. 2003 Jan 13;4:2. (PMID: 12525261)
JAMA. 2014 Jan 22-29;311(4):392-404. (PMID: 24449318)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Clin Cancer Res. 2015 Sep 15;21(18):4234-42. (PMID: 26038573)
Semin Cancer Biol. 1993 Aug;4(4):231-9. (PMID: 8400145)
Nucleic Acids Res. 2016 Jul 8;44(W1):W135-41. (PMID: 27105848)
Cancer Res. 1997 Aug 1;57(15):3126-30. (PMID: 9242437)
Substance Nomenclature:
0 (Biomarkers)
0 (MIRN125 microRNA, human)
0 (MIRN1469 microRNA, human)
0 (MIRN4530 microRNA, human)
0 (MIRN5100 microRNA, human)
0 (MIRN642 microRNA, human)
0 (MicroRNAs)
Entry Date(s):
Date Created: 20200507 Date Completed: 20210107 Latest Revision: 20240328
Update Code:
20240329
PubMed Central ID:
PMC7200710
DOI:
10.1038/s41598-020-64569-1
PMID:
32371926
Czasopismo naukowe
Pancreatic cancer (PC) is a malignancy with little/no warning signs before the disease reaches its ultimate stages. Currently early detection of PC is very difficult because most patients have non-specific symptoms leading to postponing the correct diagnosis. In this study, using multiple bioinformatics tools, we integrated various serum expression profiles of miRNAs to find the most significant miRNA signatures helpful in diagnosis of PC and constructed novel miRNA diagnosis models for PC. Altogether, 27 differentially expressed miRNAs (DEMs) showed area under curve (AUC) score >80%. The most promising miRNAs, miR-1469 and miR-4530, were individually able to distinguish two groups with the highest specificity and sensitivity. By using multivariate cox regression analyses, 5 diagnostic models consisting of different combinations of miRNAs, based on their significant expression algorithms and functional properties were introduced. The correlation model consisting of miR-125a-3p, miR-5100 and miR-642b-3p was the most promising model in the diagnosis of PC patients from healthy controls with an AUC of 0.95, Sensitivity 0.98 and Specificity 0.97. Validation analysis was conducted for considered miRNAs on a final cohort consist of the microarray data from two other datasets (GSE112264 & GSE124158) . These results provide some potential biomarkers for PC diagnosis after testing in large case-control and cohort studies.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies